After some tough times, the picture is improving for Albany Molecular
At first blush, Albany Molecular's second-quarter results seem pretty rough. Compared to last year's second quarter, total revenue declined 12% to $45.6 million, while the firm turned in a loss of $353,000 versus earnings of $7.3 million.
However, the revenue slump stemmed a 55% year-over-year decline in royalty revenue from the firm's rights to Allegra, Sanofi-Aventis'
Two out of three of the company's units showed healthy top-line growth. The discovery services segment saw a 48% jump in revenue to $9.4 million, thanks in part to a deal with Bristol-Myers Squibb
Albany Molecular still has some work to do on its turnaround, and there is no near-term replacement for the company's declining royalty revenue. But the firm has made good progress back from its slump, and that progress seems likely to continue.
For more on Albany Molecular:
Join in on the discussion:
Fool contributor Brian Gorman does not own shares in any of the companies mentioned.
More from The Motley Fool
3 Biotech Stocks to Buy in March
Why Spark Therapeutics, Albany Molecular Research, and Concert Pharmaceuticals could be great biotech stocks to buy as spring approaches.
The Cheapest Stocks in Biotech
Is now the perfect time for value investors to go bargain hunting in biotech?
3 Value Stocks Near 52-Week Lows Worth Buying
These value stocks may be down, but they're far from out!